Medication Without Panic

How to Decide About Medication Without Panic: A Neurodiversity-Informed Guide for South African Parents

Few decisions feel as emotionally charged as the question of medication. For many parents, this isn’t just a clinical discussion — it’s an emotional one.

Am I helping my child, or harming them? Are we acting too soon? What if we get this wrong?

In South Africa, these questions are rarely asked in a vacuum. They are asked in the context of school pressure, medical aid constraints, therapy access, stigma, and limited specialist availability.

Medication decisions here often sit at the intersection of support and survival.

First: Medication Does Not Treat Neurodivergence

Medication does not remove ADHD or autism. It does not change identity or personality. Instead, medication may support specific challenges that can accompany these neurotypes.

In ADHD, this might include:

• attention
• impulse control
• task initiation
• anxiety

In autism, medication is not used to treat autism itself. It may be considered when co-occurring challenges such as the following, significantly interfere with daily life:

• behavioural challenges
• anxiety
• sleep disruption
• severe irritability
• hyperactivity

This distinction matters. Medication supports function, not identity.

ADHD and Autism: Different Roles for Medication

In ADHD, stimulant medications such as methylphenidate are commonly prescribed when symptoms significantly affect learning or wellbeing. Research shows these medications can improve attention and reduce impulsivity in many children (Faraone et al., 2021).

In autism, medication is usually considered for associated challenges rather than core autistic traits. For example, methylphenidate may reduce hyperactivity, while medications such as guanfacine or risperidone may support emotional regulation or reduce severe irritability when necessary (Sturman et al., 2017; Houghton et al., 2022).

Where ADHD and autism co-occur — something increasingly recognised — treatment decisions may follow ADHD pathways while accounting for sensory and emotional regulation differences (Young et al., 2020).

The South African Reality: Access Shapes Decisions

Globally, medication is typically one support amongst many, whilst in South Africa, access to alternatives is often uneven. Many families face long therapy waiting lists, limited school support, high private therapy costs, or uneven access to remedial education.

Medication sometimes becomes the most accessible support — not necessarily the most desired one. This does not mean parents are choosing medication lightly. It means they are navigating a constrained system.

Medical Aid Realities

In South Africa, medication may be funded where therapy is not.

While Prescribed Minimum Benefits (PMBs) offer some protection, coverage for interventions like occupational therapy or psychological support can still be inconsistent, and parents may find themselves asking: Is medication the only support we can realistically access right now?

This reframes the decision. It becomes less about preference and more about practicality.

School System Pressures

South African classrooms are often large, under-resourced and not consistently neuro-affirming.

When environments cannot adapt, medication may be considered to help a child cope within the system — not because the child needs to change, but because the system cannot be flexible.

This creates a sense of urgency where parents may worry about academic failure, social exclusion and/or behavioural labelling.

Medication decisions can therefore feel tied to belonging and participation.

Cultural & Social Context

Across many communities, stigma around mental health, medication and neurodevelopmental differences remains strong.

Parents may face family resistance, social judgment and misunderstanding from schools, which just adds another critical layer to decision-making.

Medication becomes not just a medical decision, but a social one.

Specialist Access

Not all families have access to developmental paediatricians or neuroaffirming psychiatrists. Some rely on general practitioners or general paediatricians.

This can affect prescribing approaches, follow-up support and confidence in decision-making. It is understandable that parents may feel uncertain when having to make this decision.

Medication Is One Support — Not The Only One

Guidelines recommend that environmental and behavioural supports are considered alongside medication (NICE, 2018). However, when these supports are unavailable or insufficient, medication may help reduce daily strain. It is critical to believe that this is not failure, it is adaptation.

Risks and Monitoring

Like all medical interventions, medication carries risks, and common side effects may include things such as appetite suppression, sleep disruption or heightened anxiety. Therefore careful monitoring is essential, including tracking growth and wellbeing (Cortese et al., 2018).

Medication is rarely a permanent decision and many families adjust, pause, or discontinue use over time.

A Functional Decision — Not a Moral One

It is important to remember that medication is not a shortcut, an act of surrendering, or a parenting failure. It is one possible support, and in South Africa, deciding about medication often means balancing function, access to services, and participation.

The goal is not to make a child different. It is to make their world more accessible.

Final Thought

Deciding calmly does not mean deciding quickly. It means recognising the realities you are navigating and choosing the support that best reduces friction in your child’s daily life.

You are not deciding in isolation. You are deciding within the context of a system. And within that system, thoughtful support — including medication when appropriate — may simply be one way of helping your child move through the world with greater ease.

References

Cortese, S., et al. (2018). Association between ADHD medication use and growth. The Lancet Psychiatry, 5(9), 727–738.

Faraone, S. V., et al. (2021). The pharmacology of ADHD medications. Molecular Psychiatry, 26, 509–523.

Houghton, R., et al. (2022). Pharmacological treatment of irritability in autism spectrum disorder. Journal of Child Psychology and Psychiatry, 63(3), 249–262.

National Institute for Health and Care Excellence. (2018). Attention deficit hyperactivity disorder: Diagnosis and management (NICE Guideline NG87).

Sturman, N., Deckx, L., & van Driel, M. (2017). Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database of Systematic Reviews.

Young, S., et al. (2020). Guidance for identification and treatment of ADHD in individuals with autism spectrum disorder. BMC Medicine, 18, 146.